Xcorporeal, Inc.
Xcorporeal, Inc. (XCRP) Stock Competitors & Peer Comparison
See (XCRP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XCRP | $0.00 | -0.00% | 1.5K | N/A | -$0.20 | N/A |
| BMXXY | $13.83 | +0.00% | 16.3B | 32.16 | $0.43 | +0.71% |
| EBOSY | $41.94 | +0.00% | 2.1B | 22.92 | $1.83 | +3.09% |
| EBRCZ | $0.55 | +0.00% | 204.4M | -4.57 | -$0.12 | N/A |
| XVIPY | $5.70 | +4.552715654952077e+29% | 179.5M | N/A | N/A | N/A |
| NVNBW | $0.56 | +0.00% | 90.5M | -0.29 | -$1.95 | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| SCIE | $0.00 | +7.987220447284345e+24% | 492.4K | -0.01 | -$0.01 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
| SXHHF | $0.00 | -0.00% | 38.1K | -0.01 | -$0.01 | N/A |
Stock Comparison
XCRP vs BMXXY Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, BMXXY has a market cap of 16.3B. Regarding current trading prices, XCRP is priced at $0.00, while BMXXY trades at $13.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 32.16. In terms of profitability, XCRP's ROE is -3.49%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, XCRP and BMXXY have similar daily volatility (0.00).Check BMXXY's competition here
XCRP vs EBOSY Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, EBOSY has a market cap of 2.1B. Regarding current trading prices, XCRP is priced at $0.00, while EBOSY trades at $41.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 22.92. In terms of profitability, XCRP's ROE is -3.49%, compared to EBOSY's ROE of +0.08%. Regarding short-term risk, XCRP and EBOSY have similar daily volatility (0.00).Check EBOSY's competition here
XCRP vs EBRCZ Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, EBRCZ has a market cap of 204.4M. Regarding current trading prices, XCRP is priced at $0.00, while EBRCZ trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -4.57. In terms of profitability, XCRP's ROE is -3.49%, compared to EBRCZ's ROE of -2.89%. Regarding short-term risk, XCRP is less volatile compared to EBRCZ. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check EBRCZ's competition here
XCRP vs XVIPY Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, XVIPY has a market cap of 179.5M. Regarding current trading prices, XCRP is priced at $0.00, while XVIPY trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas XVIPY's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to XVIPY's ROE of +0.10%. Regarding short-term risk, XCRP is less volatile compared to XVIPY. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check XVIPY's competition here
XCRP vs NVNBW Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, NVNBW has a market cap of 90.5M. Regarding current trading prices, XCRP is priced at $0.00, while NVNBW trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.29. In terms of profitability, XCRP's ROE is -3.49%, compared to NVNBW's ROE of -0.51%. Regarding short-term risk, XCRP is less volatile compared to NVNBW. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check NVNBW's competition here
XCRP vs TRXDW Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, XCRP is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to TRXDW's ROE of -5.59%. Regarding short-term risk, XCRP and TRXDW have similar daily volatility (0.00).Check TRXDW's competition here
XCRP vs SCIE Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, SCIE has a market cap of 492.4K. Regarding current trading prices, XCRP is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is -0.01. In terms of profitability, XCRP's ROE is -3.49%, compared to SCIE's ROE of +0.00%. Regarding short-term risk, XCRP and SCIE have similar daily volatility (0.00).Check SCIE's competition here
XCRP vs GWPC Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, XCRP is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, XCRP's ROE is -3.49%, compared to GWPC's ROE of N/A. Regarding short-term risk, XCRP and GWPC have similar daily volatility (0.00).Check GWPC's competition here
XCRP vs SXHHF Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, XCRP is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, XCRP's ROE is -3.49%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, XCRP is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check SXHHF's competition here
XCRP vs DGCRF Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, DGCRF has a market cap of 21.5K. Regarding current trading prices, XCRP is priced at $0.00, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is 0.00. In terms of profitability, XCRP's ROE is -3.49%, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, XCRP is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check DGCRF's competition here
XCRP vs KKUR Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, XCRP is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to KKUR's ROE of N/A. Regarding short-term risk, XCRP is less volatile compared to KKUR. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check KKUR's competition here
XCRP vs OMRX Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, OMRX has a market cap of 5.3K. Regarding current trading prices, XCRP is priced at $0.00, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas OMRX's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to OMRX's ROE of -0.15%. Regarding short-term risk, XCRP is less volatile compared to OMRX. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check OMRX's competition here
XCRP vs IBXG Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, XCRP is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to IBXG's ROE of N/A. Regarding short-term risk, XCRP is less volatile compared to IBXG. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check IBXG's competition here
XCRP vs DMSI Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, XCRP is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, XCRP and DMSI have similar daily volatility (0.00).Check DMSI's competition here
XCRP vs AAXT Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, XCRP is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, XCRP and AAXT have similar daily volatility (0.00).Check AAXT's competition here
XCRP vs BMGP Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, XCRP is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, XCRP is less volatile compared to BMGP. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check BMGP's competition here
XCRP vs IMRSQ Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, XCRP is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, XCRP is less volatile compared to IMRSQ. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check IMRSQ's competition here
XCRP vs STBV Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, STBV has a market cap of 472. Regarding current trading prices, XCRP is priced at $0.00, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas STBV's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to STBV's ROE of -1.13%. Regarding short-term risk, XCRP is less volatile compared to STBV. This indicates potentially lower risk in terms of short-term price fluctuations for XCRP.Check STBV's competition here
XCRP vs OMDD Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, OMDD has a market cap of 310. Regarding current trading prices, XCRP is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, XCRP's ROE is -3.49%, compared to OMDD's ROE of N/A. Regarding short-term risk, XCRP and OMDD have similar daily volatility (0.00).Check OMDD's competition here
XCRP vs QMED Comparison July 2025
XCRP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XCRP stands at 1.5K. In comparison, QMED has a market cap of 17. Regarding current trading prices, XCRP is priced at $0.00, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XCRP currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, XCRP's ROE is -3.49%, compared to QMED's ROE of N/A. Regarding short-term risk, XCRP and QMED have similar daily volatility (0.00).Check QMED's competition here